CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients
Clinical Laboratory · 2026 · 72 (05/2026)
DOI: 10.7754/clin.lab.2025.250744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Laboratory, 2026. Verfasst von Sutao Zhou und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Multiple Myeloma, Bortezomib, Natural Killer T-Cells, Biomarkers, Tumor.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Zhou, S., Xu, X., Cuo, J., Sun, C., Hou, Y., Wang, X., Nana, D., & Weixun, S. (2026). CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. Clinical Laboratory, 72(05/2026). https://doi.org/10.7754/clin.lab.2025.250744
Vancouver
Zhou S, Xu X, Cuo J, Sun C, Hou Y, Wang X, et al. CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients. Clinical Laboratory. 2026;72(05/2026). doi:10.7754/clin.lab.2025.250744
BibTeX
@article{Zhou2026,
author = {Zhou, Sutao and Xu, Xueqing and Cuo, Juan and Sun, Chao and Hou, Yali and Wang, Xia and Nana, Duan and Weixun, Shi},
title = {CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple Myeloma Patients},
journal = {Clinical Laboratory},
year = {2026},
volume = {72},
number = {05/2026},
doi = {10.7754/clin.lab.2025.250744}
}
EUVIMED